Industrialization of iPSC-Derived Allogeneic Cell Therapies: Challenges and Breakthroughs?

Induced pluripotent stem cell (iPSC)–derived allogeneic immune cell therapies are poised to transform immuno-oncology, but broad adoption depends on scalable, reproducible, and cost-efficient manufacturing. This presentation highlights the industrialization of iPSC-derived NK and T-cell therapies through Cellistic’s Echo™-NK and Echo™-T manufacturing platforms.

Echo™-NK and Echo™-T address key limitations of donor-derived and autologous approaches by enabling standardized, closed, and automated bioprocesses that support consistent product quality and predictable performance from early development through commercial scale. High-density expansion and robust differentiation workflows significantly reduce manufacturing complexity and cost of goods while maintaining stringent quality attributes. Integrated control strategies ensure consistent identity, potency, and regulatory readiness. Together, these platforms enable the transition from bespoke cell therapy manufacturing to industrialized, commercially viable allogeneic immunotherapies.

www.cellistic.com